Claudio Dansky Ullmann

Head and neck squamous cell cancer and the human papillomavirus: Summary of a National Cancer Institute State of the Science Meeting, November 9–10, 2008, Washington, D.C.

David J. Adelstein, John A. Ridge, Maura L. Gillison et al. · Head & Neck · 2009 · 264 citations

Medicine, Oncology, Pathology +9

Safety and activity of alisertib, an investigational aurora kinase A inhibitor, in patients with breast cancer, small-cell lung cancer, non-small-cell lung cancer, head and neck squamous-cell carcinoma, and gastro-oesophageal adenocarcinoma: a five-arm phase 2 study

Bohuslav Melichar, Antoine Adenis, A. Craig Lockhart et al. · The Lancet Oncology · 2015 · 251 citations

Medicine, Oncology, Pharmacology +15

Randomized Phase III Study of Alisertib or Investigator’s Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma

Owen A. O’Connor, Muhıt Özcan, Eric D. Jacobsen et al. · Journal of Clinical Oncology · 2019 · 150 citations · Full text

Medicine, Oncology, Pharmacology +17

Randomized Phase II Study of Paclitaxel plus Alisertib versus Paclitaxel plus Placebo as Second-Line Therapy for SCLC: Primary and Correlative Biomarker Analyses

Taofeek K. Owonikoko, Huifeng Niu, Kristiaan Nackaerts et al. · Journal of Thoracic Oncology · 2019 · 147 citations · Full text

Medicine, Oncology, Pharmacology +16

Transoral resection of pharyngeal cancer: Summary of a National Cancer Institute Head and Neck Cancer Steering Committee Clinical Trials Planning Meeting, November 6–7, 2011, Arlington, Virginia

David J. Adelstein, John A. Ridge, David M. Brizel et al. · Head & Neck · 2012 · 103 citations · Full text

Medicine, Oncology, Surgery +15